Recro Pharma Reaches Analyst Target Price
April 05, 2019 at 08:17 AM EDT
In recent trading, shares of Recro Pharma, Inc (REPH) have crossed above the average analyst 12-month target price of $8.12, changing hands for $8.34/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..